INDIANAPOLIS, Dec. 11,
2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:
LLY) today announced updated clinical data from the international
Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible)
Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with a
range of B-cell malignancies. These data, which were presented in
oral and poster presentations at the 65th American Society of
Hematology (ASH) Annual Meeting and Exposition, continue to support
the role of pirtobrutinib in the treatment of chronic lymphocytic
leukemia or small lymphocytic lymphoma (CLL/SLL) and mantle cell
lymphoma (MCL).
"With longer follow-up, we continue to observe efficacy and
tolerability data that support the potential utility of
pirtobrutinib in CLL and B-cell lymphomas in the post-covalent BTK
inhibitor setting," said Matthew S.
Davids, M.D., M.M.Sc., Dana-Farber Cancer Institute. "These
data demonstrate the ability of pirtobrutinib to potentially
lengthen the time patients may benefit from inhibiting BTK, a key
target in these diseases. It is also encouraging to see the
promising initial data for pirtobrutinib combined with
venetoclax, which has the possibility to allow for a time-limited
regimen for patients with CLL."
"Following the two FDA accelerated approvals for pirtobrutinib
in 2023, we are excited to present these data at ASH, further
building the body of evidence for this medicine in CLL, SLL, MCL,
and other B-cell malignancies," said David
Hyman, M.D., chief medical officer, Lilly. "These data
support the potential role that pirtobrutinib, the first and only
FDA-approved non-covalent BTK inhibitor, can play in extending the
time patients may benefit from BTK inhibition therapy and provide
additional efficacy data in patients previously treated with a
covalent BTK inhibitor. We look forward to expanding our
understanding of the broader potential clinical utility of
pirtobrutinib as we continue to progress our series of randomized
Phase 3 studies in CLL, SLL, and MCL."
The labeling for pirtobrutinib contains warnings and precautions
for infections, hemorrhage, cytopenias, cardiac arrhythmias, second
primary malignancies, and embryo-fetal toxicity.
Data from the BRUIN Phase 1/2 Study
The BRUIN Phase
1/2 clinical trial is evaluating pirtobrutinib in patients
previously treated for MCL, CLL/SLL, or other non-Hodgkin lymphomas
(NHL). The efficacy data presented at ASH for CLL/SLL and MCL are
based on independent review committee (IRC) assessment. All
presentations of safety and efficacy data from the BRUIN Phase 1/2
trial utilized a cutoff date of May 5,
2023.
Chronic Lymphocytic Leukemia/Small Lymphocytic
Lymphoma
An oral presentation (Abstract #325) detailed
updated, long-term follow-up data in patients with CLL/SLL. This
data set consisted of 282 patients who had received a prior BTK
inhibitor. Patients had received a median of four prior lines of
therapy (range: 1-11). Efficacy results showed an overall response
rate (ORR), including partial response with lymphocytosis (PR-L),
of 81.6% (95% CI: 76.5, 85.9) for patients treated with
pirtobrutinib. Response rates were consistent across all subgroups
analyzed regardless of previous therapies, age, or mutation status.
With a median follow-up of 27.5 months, median progression-free
survival (PFS) was 19.4 months (95% CI: 16.6, 22.1). With a median
follow-up of 29.3 months, median overall survival (OS) was not
estimable.
In patients treated with both a prior covalent BTK inhibitor and
BCL-2 inhibitor (n=128, median of five prior lines of therapy,
range: 1-11), pirtobrutinib demonstrated an ORR, including
PR-L, of 79.7% (95% CI: 71.7, 86.3). With a median follow-up of
22.2 months, median PFS was 15.9 months (95% CI: 13.6, 17.5). With
a median follow-up of 27.4 months, the median OS was not
estimable.
In BCL-2-naïve patients (n=154, median of three prior lines of
therapy, range: 1-9), pirtobrutinib demonstrated an ORR, including
PR-L, of 83.1% (95% CI: 76.2, 88.7). With a median follow-up of
27.6 months, median PFS was 23.0 months (95% CI: 19.6, 28.4). With
a median follow-up of 31.6 months, the median OS was not
estimable.
In the CLL/SLL safety cohort (n=282), the most frequent
treatment-emergent adverse events (TEAEs) were fatigue (36.9%),
neutropenia (34.4%), diarrhea (28.4%), cough (27.3%), and contusion
(26.2%).
A second oral presentation (Abstract #326) detailed updated
analyses of genomic evolution and resistance during pirtobrutinib
therapy in patients with relapsed covalent BTK inhibitor
pre-treated CLL who subsequently developed disease progression on
pirtobrutinib monotherapy (n=88). These data showed that although
many patients harbored BTK mutations (C481 and non-C481) prior to
initiation of pirtobrutinib therapy, these baseline genomic
features did not predict response to pirtobrutinib. Moreover, while
many patients acquired mutations at progression (68%), fewer than
half were in the BTK gene.
A poster presentation (Abstract #3269) detailed updated data
from the Phase 1b portion of the
BRUIN trial, which investigated pirtobrutinib in combination with
venetoclax with or without rituximab as a two-year fixed-duration
therapy. This data set consisted of 25 patients, 17 of whom had
received a prior BTK inhibitor. Patients were enrolled into
sequential cohorts, first in the pirtobrutinib plus venetoclax (PV)
cohort (n=15) and then the PV plus rituximab (PVR) cohort (n=10).
Efficacy results showed an ORR of 96% (95% CI: 79.6, 99.9), with
40% complete responses (PV, n=7; PVR, n=3) and 56% partial
responses (PV, n=7; PVR, n=7) across the two arms. Undetectable
minimal residual disease (uMRD) was achieved by 87.5% of patients
(PV, n=12; PVR, n=9) at some time during the trial. Across the two
arms, the PFS rate at 24 months was 79.5% (95% CI: 52.0, 92.3).
The primary endpoint was safety as assessed by TEAEs graded
according to the Common Terminology Criteria for Adverse Events
(CTCAE) v5.0. The safety profiles were generally similar among both
combination treatment groups, and no dose limiting toxicities were
observed. In the PV cohort, the most frequent treatment-related AEs
were neutropenia (46.7%), nausea (46.7%), fatigue (33.3%), diarrhea
(26.7%), and decreased platelet count (26.7%). In the PVR cohort,
the most frequent treatment-related AEs were neutropenia (70.0%),
diarrhea (60.0%), nausea (40.0%), infusion-related reactions
(40.0%), and chills (30.0%). There were no apparent drug
interactions between pirtobrutinib and venetoclax.
These efficacy and safety data support the ongoing BRUIN CLL-322
Phase 3 trial evaluating two years of pirtobrutinib plus venetoclax
and rituximab versus two years of venetoclax plus rituximab in
previously treated CLL/SLL.
Mantle Cell Lymphoma
An oral presentation (Abstract
#981) detailed updated efficacy results, including in high-risk
subgroups. This data set consisted of 152 patients who had received
a prior covalent BTK inhibitor. Patients had received a median of
three prior lines of therapy (range: 1-9). Efficacy results showed
an ORR of 49.3% (95% CI: 41.1, 57.6), including 15.8% complete
responses (n=24) and 33.6% partial responses (n=51) for patients
treated with pirtobrutinib. At a median follow-up of 14.7 months,
the median duration of response (DOR) was 21.6 months (95% CI: 9.2,
27.2). Median PFS and OS were 5.6 months (95% CI: 5.3, 9.2) and
23.5 months (95% CI: 17.1, not estimable), respectively. Response
rates were consistent across subgroups regardless of prior
treatment or high-risk molecular features.
In the MCL safety cohort (n=166), the most frequent TEAEs were
fatigue (31.9%), diarrhea (22.3%), and dyspnea (17.5%).
Additionally, Lilly presented posters highlighting pirtobrutinib
in relapsed or refractory follicular lymphoma (FL), relapsed or
refractory marginal zone lymphoma (MZL), and Richter transformation
(RT).
Loxo@Lilly is studying pirtobrutinib in multiple Phase 3
studies. Details on the trials can be found by visiting
clinicaltrials.gov.
About the BRUIN Phase 1/2 Trial
The BRUIN Phase 1/2
clinical trial is the ongoing first-in-human, global, multi-center
evaluation of pirtobrutinib in patients with hematologic
malignancies, including chronic lymphocytic leukemia (CLL), small
lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The
BRUIN trial includes one of the largest prospective cohorts of BTK
inhibitor pre-treated CLL/SLL patients ever studied.
The trial includes a Phase 1 dose-escalation phase, a Phase
1b combination arm, and a Phase 2
dose-expansion phase. The primary endpoint of the Phase 1 study is
maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D).
Secondary endpoints include safety, pharmacokinetics (PK), and
preliminary efficacy measured by overall response rate (ORR) for
monotherapy. The primary endpoint of the Phase 1b study is safety of the drug combinations. The
secondary endpoints are PK and preliminary efficacy measured by ORR
for the drug combinations. The primary endpoint for the Phase 2
study is ORR as determined by an independent review committee
(IRC). Secondary endpoints include ORR as determined by
investigator, best overall response (BOR), duration of response
(DOR), progression-free survival (PFS), overall survival (OS),
safety, and PK.
About Pirtobrutinib
Pirtobrutinib is a highly
selective (300 times more selective for BTK versus 98% of other
kinases tested in preclinical studies), non-covalent (reversible)
inhibitor of the enzyme BTK.1 BTK plays a key role in
the B-cell antigen receptor signaling pathway, which is required
for the development, activation, and survival of normal white blood
cells, known as B-cells, and malignant B-cells. BTK is a validated
molecular target found across numerous B-cell leukemias and
lymphomas, including mantle cell lymphoma (MCL) and chronic
lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL).2,3 Pirtobrutinib was developed to reversibly
bind BTK, deliver consistently high target coverage regardless of
BTK turnover rate, and preserve activity in the presence of the
C481 acquired resistance mutations.
Pirtobrutinib was approved under the FDA's Accelerated Approval
pathway as Jaypirca® (pirtobrutinib) on January 27, 2023, to treat adult patients with
relapsed or refractory MCL after at least two lines of systemic
therapy, including a BTK inhibitor, and on December 1, 2023, to treat adult patients with
CLL/SLL who have received at least two prior lines of therapy,
including a BTK inhibitor and a BCL-2 inhibitor. These indications
are approved under accelerated approval based on response rate.
Continued approval for these indications may be contingent upon
verification and description of clinical benefit in a confirmatory
trial.
INDICATIONS FOR JAYPIRCA
Jaypirca is a kinase
inhibitor indicated for the treatment of
- Adult patients with relapsed or refractory mantle cell lymphoma
(MCL) after at least two lines of systemic therapy, including a BTK
inhibitor.
- Adult patients with chronic lymphocytic leukemia or small
lymphocytic lymphoma (CLL/SLL) who have received at least two prior
lines of therapy, including a BTK inhibitor and a BCL-2
inhibitor.
These indications are approved under accelerated approval based
on response rate. Continued approval for these indications may be
contingent upon verification and description of clinical benefit in
a confirmatory trial.
IMPORTANT SAFETY INFORMATION FOR JAYPIRCA®
(pirtobrutinib)
Infections: Fatal and serious infections (including
bacterial, viral, fungal) and opportunistic infections occurred in
Jaypirca-treated patients. In a clinical trial, Grade ≥3 infections
occurred in 24% of patients with hematologic malignancies, most
commonly pneumonia (14%); fatal infections occurred in 4.4%. Sepsis
(6%) and febrile neutropenia (4%) occurred. In patients with
CLL/SLL, Grade ≥3 infections occurred (32%), with fatal infections
occurring in 8%. Opportunistic infections included Pneumocystis
jirovecii pneumonia and fungal infection. Consider prophylaxis,
including vaccinations and antimicrobial prophylaxis, in patients
at increased risk for infection, including opportunistic
infections. Monitor patients for signs and symptoms, evaluate
promptly, and treat appropriately. Based on severity, reduce dose,
temporarily withhold, or permanently discontinue Jaypirca.
Hemorrhage: Fatal and serious hemorrhage has occurred
with Jaypirca. Major hemorrhage (Grade ≥3 bleeding or any central
nervous system bleeding) occurred in 3% of patients, including
gastrointestinal hemorrhage; fatal hemorrhage occurred (0.3%).
Bleeding of any grade, excluding bruising and petechiae, occurred
in 17%. Major hemorrhage occurred in patients taking Jaypirca with
(0.7%) and without (2.3%) antithrombotic agents. Consider
risks/benefits of co-administering antithrombotic agents with
Jaypirca. Monitor patients for signs of bleeding. Based on
severity, reduce dose, temporarily withhold, or permanently
discontinue Jaypirca. Consider benefit/risk of withholding Jaypirca
3-7 days pre- and post-surgery depending on type of surgery and
bleeding risk.
Cytopenias: Jaypirca can cause cytopenias, including
neutropenia, thrombocytopenia, and anemia. In a clinical trial,
Grade 3 or 4 cytopenias, including decreased neutrophils (26%),
decreased platelets (12%), and decreased hemoglobin (12%),
developed in Jaypirca-treated patients. Grade 4 decreased
neutrophils (14%) and Grade 4 decreased platelets (6%) developed.
Monitor complete blood counts regularly during treatment. Based on
severity, reduce dose, temporarily withhold, or permanently
discontinue Jaypirca.
Cardiac Arrhythmias: Cardiac arrhythmias occurred in
patients who received Jaypirca. In a clinical trial of patients
with hematologic malignancies, atrial fibrillation or flutter were
reported in 3.2% of Jaypirca-treated patients, with Grade 3 or 4
atrial fibrillation or flutter in 1.5%. Other serious cardiac
arrhythmias such as supraventricular tachycardia and cardiac arrest
occurred (0.5%). Patients with cardiac risk factors such as
hypertension or previous arrhythmias may be at increased risk.
Monitor for signs and symptoms of arrhythmias (e.g., palpitations,
dizziness, syncope, dyspnea) and manage appropriately. Based on
severity, reduce dose, temporarily withhold, or permanently
discontinue Jaypirca.
Second Primary Malignancies: Second primary malignancies,
including non-skin carcinomas, developed in 9% of Jaypirca-treated
patients. The most frequent malignancy was non-melanoma skin cancer
(4.6%). Other second primary malignancies included solid tumors
(including genitourinary and breast cancers) and melanoma. Advise
patients to use sun protection and monitor for development of
second primary malignancies.
Embryo-Fetal Toxicity: Jaypirca can cause fetal harm in
pregnant women. Administration of pirtobrutinib to pregnant rats
during organogenesis caused embryo-fetal toxicity, including
embryo-fetal mortality and malformations at maternal exposures
(AUC) approximately 3-times the recommended 200 mg/day dose. Advise
pregnant women of potential fetal risk and females of reproductive
potential to use effective contraception during treatment and for
one week after last dose.
Adverse Reactions (ARs) in Patients Who Received
Jaypirca
The most common (≥20%) ARs in the BRUIN pooled
safety population of patients with hematologic malignancies (n=593)
were decreased neutrophil count (46%), decreased hemoglobin (39%),
fatigue (32%), decreased lymphocyte count (31%), musculoskeletal
pain (30%), decreased platelet count (29%), diarrhea (24%),
COVID-19 (22%), bruising (21%), cough (20%).
Mantle Cell Lymphoma
Serious ARs occurred
in 38% of patients. Serious ARs occurring in ≥2% of patients were
pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%),
hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%).
Fatal ARs within 28 days of last Jaypirca dose occurred in
7% of patients, most commonly due to infections (4.7%), including
COVID-19 (3.1% of all patients).
Dose Modifications and Discontinuations: ARs led to dose
reductions in 4.7%, treatment interruption in 32%, and permanent
discontinuation of Jaypirca in 9% of patients. ARs resulting in
dosage modification in >5% of patients included pneumonia and
neutropenia. ARs resulting in permanent discontinuation in >1%
of patients included pneumonia.
ARs (all Grades %; Grade 3-4 %) in ≥10% of Patients:
fatigue (29; 1.6), musculoskeletal pain (27; 3.9), diarrhea (19;
-), edema (18; 0.8), dyspnea (17; 2.3), pneumonia (16; 14),
bruising (16; -), peripheral neuropathy (14; 0.8), cough (14; -),
rash (14; -), fever (13; -), constipation (13; -),
arthritis/arthralgia (12; 0.8), hemorrhage (11; 3.1), abdominal
pain (11; 0.8), nausea (11; -), upper respiratory tract infections
(10; 0.8), dizziness (10; -).
Select Laboratory Abnormalities (all Grades %; Grade 3 or 4
%) that Worsened from Baseline in ≥10% of Patients:
hemoglobin decreased (42; 9), platelet count decreased (39; 14),
neutrophil count decreased (36; 16), lymphocyte count
decreased (32; 15), creatinine increased (30; 1.6), calcium
decreased (19; 1.6), AST increased (17; 1.6), potassium decreased
(13; 1.6), sodium decreased (13; -), lipase increased (12; 4.4),
alkaline phosphatase increased (11; -), ALT increased (11; 1.6),
potassium increased (11; 0.8). Grade 4 laboratory abnormalities in
>5% of patients included neutrophils decreased (10), platelets
decreased (7), lymphocytes decreased (6).
Chronic Lymphocytic Leukemia/Small Lymphocytic
Lymphoma
Serious ARs occurred in 56% of
patients. Serious ARs occurring in ≥5% of patients were pneumonia
(18%), COVID-19 (9%), sepsis (7%), and febrile neutropenia (7%).
Fatal ARs within 28 days of last Jaypirca dose occurred in
11% of patients, most commonly due to infections (10%), including
sepsis (5%) and COVID-19 (2.7%).
Dose Modifications and Discontinuations: ARs led to dose
reductions in 3.6%, treatment interruption in 42%, and permanent
discontinuation of Jaypirca in 9% of patients. ARs resulting in
dose reductions in >1% included neutropenia; treatment
interruptions in >5% of patients included pneumonia,
neutropenia, febrile neutropenia, and COVID-19; permanent
discontinuation in >1% of patients included second primary
malignancy, COVID-19, and sepsis.
ARs (all Grades %; Grade 3-4 %) in ≥10% of Patients:
fatigue (36; 2.7), bruising (36; -), cough (33; -), musculoskeletal
pain (32; 0.9), COVID-19 (28; 7), pneumonia (27; 16), diarrhea (26;
-), abdominal pain (25; 2.7), dyspnea (22; 2.7), hemorrhage (22;
2.7), edema (21; -), nausea (21; -), pyrexia (20; 2.7), headache
(20; 0.9), arthritis/arthralgia (19; 1.8), rash (19; 0.9),
peripheral neuropathy (16; 3.6), dizziness (15; -), fall (14; 0.9),
constipation (14; -), insomnia (14; -), upper respiratory tract
infections (13; 2.7), second primary malignancy (13; 2.7), renal
insufficiency (12; 6), hypertension (12; 5), neurological changes
(12; 2.7), mucositis (12; 0.9), decreased appetite (12; -),
respiratory tract infection (11; 1.8), supraventricular tachycardia
(10; 5).
Select Laboratory Abnormalities (all Grades %; Grade 3 or 4
%) that Worsened from Baseline in ≥20% of Patients:
neutrophil count decreased (63; 45), hemoglobin decreased (48;
19), calcium decreased (40; 2.8), platelet count decreased (30;
15), sodium decreased (30; -), lymphocyte count decreased (23; 8),
ALT increased (23; 2.8), AST increased (23; 1.9), creatinine
increased (23; -), lipase increased (21; 7), alkaline phosphatase
increased (21; -). Grade 4 laboratory abnormalities in >5% of
patients included neutrophils decreased (23).
Drug Interactions
Strong CYP3A Inhibitors:
Concomitant use with Jaypirca increased pirtobrutinib systemic
exposure, which may increase risk of Jaypirca ARs. Avoid use of
strong CYP3A inhibitors with Jaypirca. If concomitant use is
unavoidable, reduce Jaypirca dosage according to approved
labeling.
Strong or Moderate CYP3A Inducers: Concomitant use with
Jaypirca decreased pirtobrutinib systemic exposure, which may
reduce Jaypirca efficacy. Avoid concomitant use of Jaypirca with
strong or moderate CYP3A inducers. If concomitant use with moderate
CYP3A inducers is unavoidable, increase Jaypirca dosage according
to approved labeling.
Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP
Substrates: Concomitant use with Jaypirca increased their
plasma concentrations, which may increase risk of adverse reactions
related to these substrates for drugs that are sensitive to minimal
concentration changes. Follow recommendations for these sensitive
substrates in their approved labeling.
Use in Special Populations
Pregnancy and
Lactation: Due to potential for Jaypirca to cause fetal
harm, verify pregnancy status in females of reproductive potential
prior to starting Jaypirca and advise use of effective
contraception during treatment and for one week after last dose.
Presence of pirtobrutinib in human milk is unknown. Advise
women not to breastfeed while taking Jaypirca and for one week
after last dose.
Geriatric Use: In the pooled safety population of
patients with hematologic malignancies, patients aged ≥65 years
experienced higher rates of Grade ≥3 ARs and serious ARs compared
to patients <65 years of age.
Renal Impairment: Severe renal impairment increases
pirtobrutinib exposure. Reduce Jaypirca dosage in patients with
severe renal impairment according to approved labeling.
PT HCP ISI COMBO DEC2023
Please see Prescribing Information and
Patient Information for Jaypirca.
About Lilly
Lilly unites caring with discovery to create medicines that make
life better for people around the world. We've been pioneering
life-changing discoveries for nearly 150 years, and today our
medicines help more than 51 million people across the globe.
Harnessing the power of biotechnology, chemistry and genetic
medicine, our scientists are urgently advancing new discoveries to
solve some of the world's most significant health challenges,
redefining diabetes care, treating obesity and curtailing its most
devastating long-term effects, advancing the fight against
Alzheimer's disease, providing solutions to some of the most
debilitating immune system disorders, and transforming the most
difficult-to-treat cancers into manageable diseases. With each step
toward a healthier world, we're motivated by one thing: making life
better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/newsroom or
follow us on Facebook, Instagram, and LinkedIn. P-LLY
Jaypirca® is a registered trademark owned by or
licensed to Eli Lilly and Company, its subsidiaries, or
affiliates.
© Lilly USA, LLC 2023. ALL
RIGHTS RESERVED.
Lilly Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about pirtobrutinib as a treatment for adult patients with
mantle cell lymphoma (MCL) after at least two lines of systemic
therapy, including a BTK inhibitor, as a treatment for adult
patients with chronic lymphocytic leukemia or small lymphocytic
lymphoma (CLL/SLL) who have received at least two prior lines of
therapy, including a BTK inhibitor and a BCL-2 inhibitor, and a
potential treatment for follicular lymphoma (FL), relapsed or
refractory marginal zone lymphoma (MZL), and Richter transformation
(RT) and reflects Lilly's current beliefs and expectations.
However, as with any pharmaceutical product, there are substantial
risks and uncertainties in the process of drug research,
development, and commercialization. Among other things, there is no
guarantee that planned or ongoing studies will be completed as
planned, that future study results will be consistent with study
results to date, or that pirtobrutinib will receive additional
regulatory approvals. For further discussion of these and other
risks and uncertainties that could cause actual results to differ
from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q
filings with the United States Securities and Exchange Commission.
Except as required by law, Lilly undertakes no duty to update
forward-looking statements to reflect events after the date of this
release.
- Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed
or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet. 2021;397(10277):892-901.
doi:10.1016/S0140-6736(21)00224-5
- Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma.
J Hematol Oncol. 2020;13(1):79. Published 2020 Jun 17.
doi:10.1186/s13045-020-00914-1
- Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine
kinase using non-covalent inhibitors in B cell malignancies. J
Hematol Oncol. 2021;14(1):40. Published 2021 Mar 6. doi:10.1186/s13045-021-01049-7
Refer
to:
|
Kyle Owens;
Owens_Kyle@lilly.com; (332) 259-3932 – media
|
|
Joe Fletcher;
jfletcher@lilly.com; (317) 296-2884 – investors
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/updated-data-from-the-bruin-phase-12-study-of-pirtobrutinib-in-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-presented-at-the-2023-ash-annual-meeting-302011905.html
SOURCE Eli Lilly and Company